Excellent session on large vessel vasculitis imaging with @petercgrayson @anisha_dua #ACR20 @RheumNow https://t.co/up5ZcGDnPt

Still more interesting lessons from GiACTA, this time re: nature of GCA flares on TCZ: - visual manifestation flares were rare - ESR or CRP raised in 3/4 of flares (so not raised in 1/4) Understanding these flares is crucial! Unizony et al @MGHMedicine #ACR20 ABST0516 @RheumNow https://t.co/WVIitov7Ut

Diagnosis in GCA is changing. Some questions from these nice Olmsted County data: - why are dx in women declining? - in the past, without imaging, were we missing GCA diagnoses? It's easy to forget how far we've come in GCA! @MayoClinic @MdWarrington #ACR20 ABST0517 @RheumNow https://t.co/QsW8BSsf1a

GCA phenotypic differences clearer again - Large vessel involvement (on USS) in GCA are a/w: - higher steroid burden - first relapses occur later - relapses harder to diagnose (symptoms less classical), but were a/w an IMT increase of about 25% (0.18mm) #ACR20 ABST0518 @RheumNow https://t.co/87zVjAm9eU

An emerging change in diagnostic (dx) modalities used in GCA? Although the leading dx modality remains a temporal a bx at 67% from 2010-2018, this is a decrease from 84% (1950-2009). Imaging is being used 19% of the time from 2010-2018 per data from Mayo Clinic. @RheumNow #ACR20 https://t.co/J97oVAGObj

• https://twitter.com/mdwarrington/status/1324827948633960453

Dr Alba reports that in GCA angiotensin II system appears to be activated. Losartan reversed changes and reduced inflammatory markers. Possible role in GCA treatment? @rheumnow #ACR20 Abstr#510 https://t.co/IPp3lD1BUH

#ACR20 year in review by @JYazdanyMD latest data PEXIVAS and SEMIRA trials on corticosteroids - would you change your clinical practice to minimize even low dose Corticosteroids in RA and Vasculitis? @RheumNow https://t.co/l7PTyANpjq https://t.co/MRGbsjaGae

• DEFINE_ME
• https://www.nejm.org/doi/full/10.1056/nejmoa1803537

APS induced by CoViD-19: plenary session 1- another reason we need to break down the silos and involve rheumatologist more! Should we be using anticoagulation in these patients? #ACR20 @RheumNow @OSUWexMed

Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis https://t.co/1kqWeBcEDq #gca #GmCSFinh Novel MOA , big unmet need

• Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare…